Compositions and methods for the treatment of tumor hematopoietic origin

Patent metadata

Field	Value
Publication number	US-2017362318-A1
Application number	US-201715406583-A
Country	US
Kind code	A1
Filing date	Jan 13, 2017
Priority date	May 8, 2002
Publication date	Dec 21, 2017
Grant date	—

Abstract

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

First claim

What is claimed is:

1 . Isolated nucleic acid having a nucleotide sequence that has at least 80% nucleic acid sequence identity to:
(a) a DNA molecule encoding the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6), and FIG. 8 (SEQ ID NO: 8); (b) a DNA molecule encoding the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6), and FIG. 8 (SEQ ID NO: 8), lacking its associated signal peptide; (c) a DNA molecule encoding an extracellular domain of the polypeptide having the amino acid selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6) and FIG. 8 (SEQ ID NO: 8), with its associated signal peptide: (d) a DNA molecule encoding an extracellular domain of the polypeptide having the amino acid selected from the group consisting of the amino acid sequence show n in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6) and FIG. 8 (SEQ ID NO: 8). lacking its associated signal peptide; (e) the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO: 1), FIG. 3 (SEQ ID NO :3), FIG. 5 (SEQ ID NO: 5) and FIG. 7 (SEQ ID NO: 7); (f) the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO: 1), FIG. 3 (SEQ ID NO: 3), FIG. 5 (SEQ ID NO: 5) and FIG. 7 (SEQ ID NO: 7); or (g) the complement of (a), (b), (c), (d), (e) or (f).

2 . Isolated nucleic acid having:
(a) a nucleotide sequence that encodes the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6) and FIG. 8 (SEQ ID NO: 8); (b) a nucleotide sequence that encodes the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6) and FIG. 8 (SEQ ID NO: 8), lacking its associated signal peptide; (c) a nucleotide sequence that encodes an extracellular domain of the polypeptide having the amino acid selected from the group consisting of the amino acid sequence show n in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6) and FIG. 8 (SEQ ID NO: 8) with its associated signal peptide; (d) a nucleotide sequence that encodes an extracellular domain of the poly peptide having the amino acid selected from the group consisting of the amino acid sequence show n in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6) and FIG. 8 (SEQ ID NO: 8), lacking its associated signal peptide; (e) the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO: 1), FIG. 3 (SEQ ID NO: 3), FIG. 5 (SEQ ID NO: 5) and FIG. 7 (SEQ ID NO: 7); (f) the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO: 1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO: 5) and FIG. 7 (SEQ ID NO: 7); or (g) the complement of (a), (b), (c), (d), (e) or (f).

3 . Isolated nucleic acid that hybridizes to:
(a) a nucleic acid that encodes the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6) and FIG. 8 (SEQ ID NO: 8); (b) a nucleic acid that encodes the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6) and FIG. 8 (SEQ ID NO: 8), lacking its associated signal peptide; (c) a nucleic acid that encodes an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6) and FIG. 8 (SEQ ID NO: 8), with its associated signal peptide; (d) a nucleic acid that encodes an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6) and FIG. 8 (SEQ ID NO: 8), lacking its associated signal peptide; (e) the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO: 1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO: 5) and FIG. 7 (SEQ ID NO: 7); (f) the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO: 1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO: 5) and FIG. 7 (SEQ ID NO: 7); or (g) the complement of (a), (b), (c), (d), (e) or (f).

4 . The nucleic acid of claim 3 , wherein the hybridization occurs under stringent conditions.

5 . The nucleic acid of claim 3 which is at least about 5 nucleotides in length.

6 . An expression vector comprising the nucleic acid of claim 1 , 2 or 3 .

7 . The expression vector of claim 6 , wherein said nucleic acid is operably linked to control sequences recognized by a host cell transformed with the vector.

8 . A host cell comprising the expression vector of claim 7 .

9 . The host cell of claim 8 which is a CHO cell, an E. coli cell or a yeast cell.

10 . A process for producing a polypeptide comprising culturing the host cell of claim 8 under conditions suitable for expression of said polypeptide and recovering said polypeptide from the cell culture.

11 . An isolated polypeptide having at least 80% amino acid sequence identity to:
(a) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6) and FIG. 8 (SEQ ID NO: 8); (b) the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6) and FIG. 8 (SEQ ID NO: 8), lacking its associated signal peptide; (c) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6) and FIG. 8 (SEQ ID NO: 8), with its associated signal peptide; (d) an extracellular domain of the polypeptide having the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6 (SEQ ID NO: 6) and FIG. 8 (SEQ ID NO: 8), lacking its associated signal peptide; (e) a polypeptide encoded by the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO: 1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO: 5) and FIG. 7 (SEQ ID NO: 7); or (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence selected from the group consisting of the nucleotide sequence shown in FIG. 1 (SEQ ID NO: 1), FIG. 3 (SEQ ID NO:3), FIG. 5 (SEQ ID NO: 5) and FIG. 7 (SEQ ID NO: 7).

12 . An isolated polypeptide having:
(a) the amino acid sequence selected from the group consisting of the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2), FIG. 4 (SEQ ID NO: 4), FIG. 6

Assignees

• Genentech Inc

Inventors

• Crowley Craig
• De Sauvage Frederic J
• Eaton Dan L
• Ebens Jr Allen
• Elkins Kristi
• Hongo Jo-Anne S
• Junutula Jagath Reddy
• Polson Andrew
• Ross Sarajane
• Smith Victoria
• Vandlen Richard L
• Zheng Bing

Classifications

• A61P35/04

  specific for metastasis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/575

  for cancer · CPC title